Transgenic/Behavior Core

摘要 转基因小鼠模型已成为阿尔茨海默病（AD）和其他人类疾病研究的重要工具。 神经退行性疾病AD小鼠模型的认知和行为评估提供了最终的 表型，可以评估病理机制和/或生物标志物，并有助于识别 有希望的进一步临床研究的目标。对20种AD鼠标线的准确性和可用性进行了验证， 其表型的有效性和稳健性对于所提出的行为、药理和 本PO 1提案的项目2和3中描述了免疫学研究。的总体目标 转基因/行为核心（核心C）是支持独立和协同的动物和行为 这些项目的要求。其具体目标是：1）建立和维持转基因和突变型AD 小鼠模型系，2）进行AD小鼠模型的综合行为表型分析，和3） 确定药理学和免疫学干预对特定 认知/行为过程。为了实现这些目标，核心C将利用专门住房， 纽约大学啮齿动物行为实验室（NYU-RBL）的行为测试设施，以及专门的专业知识 和人员来实施一个大规模的，全面的行为表型电池，包括两个 “传统”测试和创新的触摸屏范例。核心的这些价值特性将提供实验室- 独立的标准化和跨多个项目的时间/成本效益，以及帮助最大限度地提高 AD小鼠模型表型分析结果的稳健性和临床转化。

SUM M ARY / ABSTRACT Transgenic mouse models have been instrumental to research on Alzheimer’s disease (AD) and other human neurodegenerative disorders. Cognitive and behavioral assessment of AD mouse models provides the ultimate phenotype for which pathological mechanisms and/or biomarkers can be evaluated, and helps identify promising targets for further clinical investigation. The veracity and availability of twenty AD mouse lines and the validity and robustness of their phenotypes are critical to the proposed behavioral, pharmacological and immunological studies described in Projects 2 and 3 of this PO1 proposal. The overall goal of the Transgenic/Behavior Core (Core C) is to support the independent and synergistic animal and behavioral requirements of these Projects. Its specific aims are to 1) establish and maintain transgenic and mutant AD mouse model lines, 2) perform comprehensive behavioral phenotyping of the AD mouse models and 3) determine the impact of pharmacological and immunological interventions on specific cognitive/behavioral processes. To meet these aims, Core C will leverage specialized housing and behavioral testing facilities in the NYU Rodent Behavior Laboratory (NYU-RBL), as well as dedicated expertise and personnel to implement a large-scale, comprehensive behavioral phenotyping battery that includes both “traditional” tests and innovative touchscreen paradigms. These value features of the Core will provide lab- independent standardization and time/cost-efficiency across the multiple Projects, as well as help maximize the robustness and clinical translation of AD mouse model phenotyping results.